|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2008 / October 2008 / October 15, 2008 Vitamin B fails to slow Alzheimers spread |
A special type of collagen may provide protection against Alzheimers disease
Author Terry Pratchett flabbergasted to receive knighthood
Sack lunches may not provide adequate nutrients to preschooler
Packing lunch for your child might not be a good idea, for a new study has found that sack lunches may not regularly provide adequate nutrients for the growth and development of young children. ANI
Health-monitoring system helps maintain older adults well-being
Many older adults want to remain active and independent for as long as possible. Now, researchers from University of Missouri suggest that installing health monitoring system can help keep check on the health of the elderly and ensure their privacy. ANI
New drug shows potential to treat angina, other cardiac problems
A compound, designed to prevent chest pains in heart patients, could act as a drug to treat angina and possibly other cardiac pathologies, according to a study on animals. ANI
A new study from University of California, San Diego School of Medicine has found that high doses of vitamin B fail to slow down cognitive decline in Alzheimers patients.
Washington, Oct 15 : A new study from University of California, San Diego School of Medicine has found that high doses of vitamin B fail to slow down cognitive decline in Alzheimer's patients.
The researchers sought to determine whether reduction of an amino acid called homocysteine would reduce the risk of Alzheimer's disease or slow its progression.
Homocysteine is known to be involved in neurological disease, including Alzheimer's, and B vitamins affected its metabolism. Therefore, it was thought that B vitamin supplements might offer a new therapeutic approach in treating Alzheimer' disease.
"Prior studies using B vitamin supplementation to reduce homocysteine levels in patients with Alzheimer's weren't large enough, or of long enough duration to effectively assess their impact on cognitive decline," said Dr Paul S. Aisen, professor of neurosciences at the University of California, San Diego School of Medicine.
"This study of several hundred individuals over the course of 18 months showed no impact on cognition, although it resulted in lower levels of homocysteine in these patients," he added.
During the study, the 409 participants with mild or moderate Alzheimer's received folic acid and vitamins B6 and B12 for 18 months.
They were randomly assigned to two groups of unequal size; to increase enrolment, 60 percent were treated with high-dose supplements and the remaining 40 percent treated with identical dosages of placebo.
A total of 340 participants (202 in active treatment group and 138 in placebo group) completed the trial while taking study medication.
The cognitive abilities were measured via testing with the Alzheimer Disease Assessment Scale (ADAS-cog).
The researchers found that the ADAS-cog score did not differ significantly between treatment groups, but that symptoms of depression were more common in the high-dose supplement group.
"Our study does not support the treatment of individuals with mild to moderate Alzheimer's disease and normal vitamin levels with B vitamin supplements," said the authors.
The study is published in Journal of the American Medical Association (JAMA).
ANI
